Who are Tanreqing capsule simulator's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Compound Ciwujia Granules, Guipi Granules, Compound danshen dripping pills, Xiaojin Pill, Xueshuantong lyophilized powder, Xueshuanxinmaining tablet, XueBiJing Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tanreqing-capsule-simulator.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tanreqing capsule simulator — Competitive Intelligence Brief

Tanreqing capsule simulator (Tanreqing capsule simulator) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine. Area: Respiratory.

phase 3 Traditional Chinese medicine Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Tanreqing capsule simulator (Tanreqing capsule simulator) — Jiangsu Famous Medical Technology Co., Ltd.. Tanreqing capsule simulator is used to treat cough and other respiratory symptoms by modulating the body's immune response and reducing inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Tanreqing capsule simulator TARGET	Tanreqing capsule simulator	Jiangsu Famous Medical Technology Co., Ltd.	phase 3	Traditional Chinese medicine
Compound Ciwujia Granules, Guipi Granules	Compound Ciwujia Granules, Guipi Granules	Heilongjiang Quanle Pharmaceutical Co., Ltd.	marketed	Herbal combination / Traditional Chinese Medicine
Compound danshen dripping pills	Compound danshen dripping pills	Tasly Pharmaceuticals, Inc.	marketed	Traditional Chinese medicine preparation; antiplatelet/anticoagulant agent
Xiaojin Pill	Xiaojin Pill	Zhejiang Provincial People's Hospital	marketed	Traditional Chinese medicine (herbal formulation)
Xueshuantong lyophilized powder	Xueshuantong lyophilized powder	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine extract
Xueshuanxinmaining tablet	Xueshuanxinmaining tablet	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine formulation
XueBiJing Injection	XueBiJing Injection	Nanjing Medical University	marketed	Herbal extract / Traditional Chinese Medicine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine class)

Shanghai University of Traditional Chinese Medicine · 2 drugs in this class
Jiangsu Famous Medical Technology Co., Ltd. · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Sichuan Jishengtang Pharmaceutical Co., Ltd. · 1 drug in this class
Tasly Pharmaceutical Group Co., Ltd · 1 drug in this class
China Academy of Chinese Medical Sciences · 1 drug in this class
The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
Dongzhimen Hospital, Beijing · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tanreqing capsule simulator — Competitive Intelligence Brief. https://druglandscape.com/ci/tanreqing-capsule-simulator. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab